Pfizer and manufacturer Tris Pharma have agreed to hand over $41.5 million to lay to rest a 2023 lawsuit accusing the ...

P fizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they ...

Texas Attorney General Paxton secures a $41.5 million settlement with Pfizer and Tris Pharma over allegations of providing ...

Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded ...

The settlement resolves a 2023 lawsuit that accused the pharmaceutical companies of manipulating quality control tests of a medication used to treat ADHD.

The MarketWatch News Department was not involved in the creation of this content. -- Positive Phase 3 pivotal trial results for cebranopadol accepted as a Scientific Abstract oral presentation -- -- ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX®, an extended-release suspension containing ...

Pfizer and Tris Pharma agreed to pay $41.5 million to settle allegations they altered testing methods to ensure their ADHD ...

Pfizer Inc. and Tris Pharma Inc. will pay the state of Texas $41.5 million to settle claims that it allegedly provided ...

Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas ...